ABSTRACT -Drug-induced QT interval prolongation is a critical issue in development of new chemical entities, so the pharmaceutical industry needs to evaluate risk as early as possible. Common marmosets have been in the limelight in early-stage development due to their small size, which requires only a small amount of test drug. The purpose of this study was to determine the utility of telemetered common marmosets for predicting drug-induced QT interval prolongation. Telemetry transmitters were implanted in common marmosets (male and female), and QT and RR intervals were measured. The QT interval was corrected for the RR interval by applying Bazett's and Fridericia's correction formulas and individual rate correction. Individual correction showed the least slope for the linear regression of corrected QT (QTc) intervals against RR intervals, indicating that it dissociated changes in heart rate most effectively. With the individual correction method, the QT-prolonging drugs (astemizole, dl-sotalol) showed QTc interval prolongations and the non-QT-prolonging drugs (dl-propranolol, nifedipine) did not show QTc interval prolongations. The plasma concentrations of astemizole and dl-sotalol associated with QTc interval prolongations in common marmosets were similar to those in humans, suggesting that the sensitivity of common marmosets would be appropriate for evaluating risk of drug-induced QT interval prolongation. In conclusion, telemetry studies in common marmosets are useful for predicting clinical QT prolonging potential of drugs in early stage development and require only a small amount of test drug.
INTRODUCTION
Several drugs have been withdrawn from the market recently due to cardiovascular side effects associated with a ventricular tachyarrhythmia known as Torsades de Pointes (TdP) (Redfern et al., 2003) . Because most drugs that induce TdP in man prolong the QT interval (Redfern et al., 2003) , greater emphasis is placed on identifying QT prolongation risk of new chemical entities in early stage development. In that early stage, in vitro tests for screening QT risk, such as human ether-a-go-go-related gene (hERG) and action potential duration (APD) assays, are performed mainly because of the limited amount of test substance required (Guth et al., 2004) . However, in vitro tests do not take into account such effects as the potential impact of plasma protein binding, formation of active metabolites, or additional cardiac hemodynamics, and the results may be inconsistent with clinical QT outcomes. The predictability of in vivo tests using telemetered dogs or monkeys for the clinical QT liability of drugs has been validated (Toyoshima et al., 2005; Ando et al., 2005; Hanson et al., 2006) but a considerably larger amount of test substance is needed than with in vitro testing. Recently, common marmosets have been in the limelight as experimental animals in the early development stage because of their small size and thus small amount of test drug needed. In 2002, we reported that common marmosets show the desired responses for the safety assessment of several drugs that affect the cardiovascular system including QT interval (Horii et al., 2002) . However, this study focused on the utility of the animal for the entire -ity of drug-induced QT interval prolongation.
When examining the effect of a drug on QT interval, it is necessary to correct the QT intervals against RR intervals using QT/RR correction formulas because the QT interval adapts to changes in the RR interval (or heart rate). General correction formulas from Bazett (Bazett, 1920) and Fridericia (Fridericia, 1920) have been used to evaluate the QT liability of drugs in dogs and monkeys (Toyoshima et al., 2005; Ando et al., 2005; Hanson et al., 2006) , however, an individual rate correction was recently proposed to be more appropriate (Miyazaki and Tagawa, 2002; Holzgrefe et al., 2007) . However, there has been no information available on this individual QT/RR correction method used with common marmosets.
The purpose of this study was twofold.
(1) To determine the QT correction method suitable for use with common marmosets from among the two generally used formulas and the individual rate correction. (2) To demonstrate the accuracy of prediction of the QT liability of drugs by comparing the effects on QT interval of clinically QT-prolonging drugs (astemizole and dl-sotalol) and non-QT-prolonging drugs (dl-propranolol and nifedipine) with clinical observations and in vitro hERG inhibitions.
MATERIALS AND METHODS

Animals
Common marmosets obtained from Clea Japan, Inc. (Tokyo, Japan) were used in this study. The animals were handled according to the protocol approved by the Ethical Committee for Animal Welfare of Chugai Pharmaceutical Co., Ltd.. The animals received solid food once daily and water ad libitum, and were individually housed in stainless steel cages (W: 465 mm, D: 465 mm, H: 565 mm) in hr of light (7:00-19:00), a temperature range of 28 ± 2ºC, and a relative humidity range of 55 ± 15%.
Drugs
Two compounds known to cause QT interval prolongation in humans, the histamine H 1 blocker astemizole and the anti-arrhythmic drug dl-sotalol hydrochloride (dl-sotalol), and two compounds known to not cause QT interval -onist dl-propranolol hydrochloride (dl-propranolol) and the calcium channel blocker nifedipine, were selected for this study (Omata et al., 2005) . All compounds were purchased from Sigma Chemical Co. (St. Louis, MO, USA). dl-Sotalol and dl-propranolol were dissolved in distilled water (DW). Nifedipine or astemizole was formulated as a suspension in 0.5% carboxyl-methylcellulose sodium (CMC) (Wako Pure Chemical Industries, Ltd., Osaka, Japan) in DW with or without 1.5% dimethyl sulfoxide (DMSO) (Wako Pure Chemical Industries, Ltd.).
Animal preparation
Four common marmosets (250-400 g, 2 males and 2 females) were surgically instrumented with telemetry transmitters (TL11M2-C50-PXT, Data Sciences International, Arden Hills, MN, USA). After intramuscular injections of ketamine hydrochloride at 50 to 70 mg/kg and xylazine hydrochloride at 5 to 7 mg/kg, the anesthetized animals were instrumented subcutaneously with leads of a limb lead II electrocardiogram (ECG). The positive lead was positioned between the left 7 th and 8 th ribs while the negative lead was positioned on the first sternum. The telemetered animals were given 25 mg/head streptomycin intramuscularly post surgery and were allowed to recover for at least 1 month.
ECG recording
ECG was transmitted to the telemetry transmitter at a time constant of 2 sec. The transmitted ECG data was recorded by a data acquisition system (ART, Data Sciences International) at 1 kHz and analyzed using data analysis software (HEM ver 4.1, NOTOCORD Systems SAS, Croissy sur Seine, France). The ECG measurement was performed under quiet conditions in an animal room remote from the data acquisition, analysis and storage room. Entry to the animal room was restricted except for physical checks, dosing, feeding the animals and cleanup of room and cages.
Cardiovascular ECG
First, we conducted a comparative evaluation of three QT/RR correction methods. ECGs were recorded continuously for 24 hr, and QT and RR intervals were measured every 6 min over 24 hr with 10 consecutive ECG waves analyzed at each point. The QT interval was then corrected against the RR interval by generic formulas proposed by Bazett (1920) and Fridericia (1920) and the individual rate correction derived from the method initially described by Spence et al. (1998) and subsequently mod-(QTc) intervals were re-expressed to the reference cycle length (RR ref of the methods. The reference cycle length was determined using the average common marmoset heart rate of in this study were: To evaluate the effects of the test substances, test compound solutions (2 ml/kg) were orally administered to the telemetered animals at around 13:30. The animals were fasted approximately 5 hr before administration and approximately 4 hr after administration. The test drugs and doses administered were astemizole (10 and 30 mg/kg), dl-sotalol (5 and 15 mg/kg), dl-propranolol (30 mg/kg), and nifedipine (30 mg/kg) with at least 1-week interval between administrations of different compounds and different doses. The doses for astemizole and dl-sotalol were determined to exemplify the dose-dependent effects on QT interval, taking into consideration data from a previous study using telemetered cynomolgus monkeys (Ando et al., 2005) . The doses of dl-propranolol and nifedipine were selected so that the peak plasma concentration after administration would be over the efficacious concentration in clinic (Rocher et al., 1985; Zylber-Katz et al., 1988) . Vehicle controls were administered in the same manner as test compounds. The QT and 7, 12 and 24 hr post-dose were obtained from the analysis of 10 consecutive waves. The heart rate at the same time point was calculated from the RR intervals. The average used as the baseline.
Pharmacokinetics
To determine plasma concentrations of test substances, each test substance was administered orally at each dose to non-telemetered marmosets (250-400 g, 2 males and 2 females). Each animal received the test substance identical to the cardiovascular study design. Approximately 0.15 ml of blood was collected from the tail vein and placed in a heparinized tube at the following time points: 0.5, 1, 2, 4, 7 hr post-dose for astemizole, dl-sotalol and dl-propranolol and 0.25, 0.5, 1, 2, 4 hr post-dose for nifedipine. Plasma samples were obtained after centrifuconcentrations by LC-MS/MS. Desmethylastemizole, a metabolite of astemizole that inhibits the rapidly activatcurrents (I Kr ) mainly responsible for ventricular repolarization (Vorperian et al., 1996; Zhou et al., 1999) , was also measured by LC-MS/MS. The protein binding rates of astemizole, desmethylastemizole and dl-sotalol in common marmosets were measured using an equilibrium dialysis method. Plasma samples and isotonic phosphate buffer (100 μl per chamber) were placed in the sample side and dialysis side, respectively, of the wells of a 96-well equilibrium dialysis block (HTD96b, HTDialysis, LLC, Gales Ferry, CT) bisected with a dialysis membrane (MWCO 12-14K, HTDialysis, LLC). After incubation at 37ºC for 4 hr, concentrations of the test articles in the plasma (total) and the buffer (unbound) were determined by LC-MS/MS.
Statistical analysis
For comparative evaluation of the QT/RR correction methods, linear regression equations for the QTc intervals against RR intervals were obtained by the meth--iation (CV) of the equations were calculated. When the slope was close to zero, the correction method was considered to have eliminated the effect of heart rate change on the QT interval. In addition, when the CV was less than 10%, the accuracy of the equation was considered appropriate (Matsunaga et al., 1997) . The slopes obtained from Bazett's, Fridericia's and individual formulas were the homogeneity of variance using Bartlett's test (Bartlett, 1937) .
The data for astemizole and dl-sotalol were statistically analyzed for homogeneity of variance using Bartlett's test (Bartlett, 1937) and were then compared with the time-matched vehicle control values using parametric Dunnett's test when the variance was homogeneous, or non-parametric Dunnett's test when the variance was heterogeneous (Dunnett, 1964) . The data for dl-propranolol and nifedipine were statistically analyzed for homogeneity of variance by the F-test (JIS, 1965) and then compared with the time-matched vehicle control values using Student's t-test (JIS, 1965) when the variance was homogeneous, or Welch's t-test (Welch, 1938) when the variance was heterogeneous.
Values in the data represent the mean ± S.D. of four animals. All statistics were calculated using the SAS system (Version 8.2, SAS Institute, Cary, NC, USA) and val-
RESULTS
QT-RR relationships and comparative evaluation of QT correction methods
The mean heart rates and mean QT intervals of four common marmosets for 24 hr were 148 ± 10 bpm (407 ± 29 msec for RR interval) and 144 ± 2 msec, respectively. A typical QT-RR relationship in a single subject is given in Fig. 1 . The relationship clearly shows positive correlations between QT and RR intervals (slope = 0.1598). Similar observations were also observed in the other three animals. The QT-RR data were expressed as QTc-RR plots from the application of the two generic formulas and individual rate correction (Fig. 2) . As shown in Table  1 , the slope of the linear regression obtained from individual rate correction (slope = 0.0031) was closer to zero than from Bazett's (slope = 0.0054) or Fridericia's (slope = 0.0690). However, the slope from individual correction -one from Bazett's. All CV values of these linear regressions were within acceptable range (less than 10%). These indicate that the individual correction method showed the most effective independence from the RR interval, even though results from Bazett's formula were comparable. Effects of QT-prolonging and non-QT-prolonging drugs on heart rate, QT and QTci intervals Fig. 3 shows representative ECG waveforms recorded before and after the administration of astemizole at 30 mg/kg and Fig. 4 shows time courses for heart rate, QT and QTci interval, and plasma concentration of the test drugs used. None of the vehicle controls used in this study showed effects on the parameters tested, except for transient increases in heart rate and slight shortenings of QT interval immediately after administration. Astemizole by 49 and 105 msec, respectively, and QTci interval by 48 and 98 msec, respectively, maximally from the baseline at 2 hr post-dose without affecting heart rate ( Fig. 4A) . Peak plasma concentrations of astemizole and desmethylastemizole were 0.025 ± 0.018 and 0.268 ± 0.250 μM, respectively, at 0.5 hr after 10 mg/kg administration, and 0.033 ± 0.017 at 0.5 hr and 0.403 ± 0.176 μM at 2 hr, respec- tively, after 30 mg/kg administration. dl-Sotalol showed no effect for any parameter at 5 mg/kg, but at 15 mg/kg 80 msec, respectively, maximally from the baseline at 1 hr post-dose with a slight decrease in heart rate ( 5 and 15 mg/kg were 3.90 ± 1.71 and 5.29 ± 2.42 μM, respectively, at 1 hr post-dose. On the other hand, dl-Propranolol at 30 mg/kg showed no effect for any parameter tested and the peak plasma concentration was 3.73 ± 2.66 -cious concentration in clinic (Rocher et al., 1985) . Nifedbpm above baseline) and shortened QT interval by 41 msec, however, no effect on QTci interval was observed (Fig. 4D) . The peak plasma concentration was 1.11 ± 1.52 Fig. 4B . Effects of dl -val, and QTci interval. The bottom-most graph shows the plasma concentrations for each test drug. Data points represent the Vol. 33 No. 3 centration in clinic (Zylber-Katz et al., 1988) . Table 2 shows the plasma concentrations associated with QTci interval prolongation in common marmosets compared with plasma concentrations associated with QT prolongation or TdP in clinic and 50% inhibitory concentrations on hERG. The plasma concentrations of non-QT-prolonging drugs are not shown because no QTc interval prolongation was observed, but hERG inhibitory potential is shown. The plasma concentrations of astemizole (astemizole plus desmethylastemizole) and dl-sotalol associated with QTc interval prolongation in common marmosets were almost consistent with those associated with clinical QT prolongation or TdP. However, free plasma concentrations associated with QTc interval prolongation in common marmosets showed a link with in vitro hERG inhibitory potency for astemizole/desmethylastemizole but not for dl-sotalol.
Comparison of QTc interval prolongation in common marmosets with clinical QT prolongation and hERG inhibition
DISCUSSION
The purpose of this study was to determine a suitable QT/RR correction method applicable to common marmoset and to evaluate the predictability of the clinical QT liability of drugs using the present telemetry model. Based on linear regression analysis of QTc interval against RR interval, we found that individual rate correction in accordance with the analysis of covariance (Miyazaki and Tagawa, 2002) best corrected the effect of RR interval on QT interval in comparison with the generic formulas tested. When corrected using the individual correction method, the QT-prolonging drugs tested showed QTc interval prolongation, whereas the non-QT-prolonging drugs did not show QTc interval prolongation, suggesting that the marmoset telemetry model has potential to be utilized in prediction of a drug's liability to lengthen QTc interval in humans.
Since the ventricular repolarization period varies with heart rate, QT/RR correction formulas such as Bazett's and Fridericia's have been widely used to correct the QT interval for the RR interval. However, these standard correction formulas have been shown to have limitations in comparison with the new approach of finding the relationship in an individual (Miyazaki and Tagawa, 2002) . As with telemetry studies in other species (Miyazaki and Tagawa, 2002; Kano et al., 2005; Holzgrefe et al., 2007) , with common marmosets the individual method showed better corrections than both traditional formulas, although the corrections from Bazett's were nearly comparable. Nifedipine, which has no QT-prolonging risk in clinic, was reported to cause tachycardia and false QTc interval prolongation in a canine telemetry study using Fridericia's formula (Toyoshima et al., 2005) . Verapamil, anoth- Hoppu et al. 1991 and Saviuc et al. 1993, c Kimura et al. 1996, d Zhou et al. 1999, e Kirsch et al. 2004, f Kawakami et al. 2006 , g Zhang et al. 1999 er calcium channel blocker, also caused tachycardia and false QT-prolonging results in the same canine study (Toyoshima et al., 2005) and in a monkey study using Bazett's formula (Ando et al., 2005) . The explanation given for the QTc overestimations was that the heart rate was out of a valid correction range due to hyper-tachycardia (130-170% of baseline value) (Ando et al., 2005; Toyoshima et al., 2005) . Contrary to those studies and with the use of individual correction, nifedipine showed no QTc interval prolongation, although it did cause -ings strongly support the utility of the individual correction method.
Astemizole at 10 mg/kg and dl-sotalol at 15 mg/kg sig--centrations of 0.293 (astemizole plus desmethylastemizole) and 5.29 μM, respectively. We used the combined plasma concentrations of astemizole and desmethylastemizole for comparison with clinical outcomes because desmethylastemizole was reported to have almost the same potential as astemizole for I Kr /hERG blockade and action potential prolongation (Vorperian et al., 1996; Zhou et al., 1999) . The plasma concentrations of astemizole and dl-sotalol in common marmosets were similar to those in humans associated with QT prolongation/TdP (0.134-0.545 and 5.54 μM, respectively) (Hoppu et al., 1991; Saviuc et al., 1993; Kimura et al., 1996) , suggesting that sensitivity of common marmosets is appropriate for predicting drug-induced QT interval prolongation in clinic.
Since the blockade of I Kr encoded by hERG appears to be the main mechanism of drugs that prolong QT interval (Redfern et al., 2003) , assessments on hERG have been widely performed for QT screening. It was reported that the IC 50 values in the hERG/I Kr assay correlate well with the free plasma concentrations associated with QT interval prolongation (Webster et al., 2002) . Indeed, the free plasma concentrations of astemizole and desmethylastemizole associated with QTc interval prolongation in this study were 0.3 and 9 nM, respectively, which were close to hERG IC 50 s of 0.9 and 1 nM, respectively (Zhou et al., 1999) . On the other hand, dl-sotalol has very weak hERG inhibitory potential with an IC 50 value of 278 μM (Kirsch et al., 2004) , but apparently caused QTc interval prolongation at the free plasma concentration of 4.99 μM in common marmosets. dl-Sotalol also prolonged QTc intervals at a free plasma concentration of 7.2 μM in anesthetized dogs (Schnelle and Garrett, 1973; Tabo et al., 2006) and 5.3 μM in humans (Carr et al., 1995; Kimura et al., 1996) . The reason why dl-sotalol shows such weak hERG blockade even though it prolongs QT interval via the I K blockade (Antonaccio and Gomoll, 1993 ) is unclear, but it is considered that the QT-prolonging effect of dl-sotalol might be caused, at least partially, through a mechanism other than direct hERG inhibition. Contrary to the case of dl-sotalol, dl-propranolol showed no QTc interval prolongation even though it has apparently stronger potential than dl-sotalol to inhibit hERG (IC 50 = 3.9 μM) (Kawakami et al., 2006) . It was reported that dl-propranolol inhibits not only I Kr /hERG but also I Na (Varro et al., 1990) , leading to a shortening of APD in isolated guinea pig papillary muscles at 3 μM and above (Hayashi et al., 2005) or no effect on QTc interval, as in the present study, in conscious dogs up to 30 mg/kg (Toyoshima et al., 2005) . These findings suggest that drugs that may have QT-prolonging mechanisms other than hERG blockade or inhibit not only hERG but also other ion channels might show discrepancies between hERG inhibitory potential and actual QT interval prolongation, indicating that a ventricular repolarization study would be needed for accurate evaluation of the QT liability of drugs. In fact, the International Conference on Harmonization S7B guideline (ICH S7B guideline) requires not only in vitro hERG studies but also in vivo QT studies for the assessment of the potential risk of QT interval prolongation.
The present study has some limitations. Both RR and 1. Horii et al. (2002) showed that common marmosets have diurnal changes in heart rate and so the variation of the RR interval was probably caused by circadian rhythm.
observed in other species such as dogs, pigs and humans (Harada et al., 2005; Kano et al., 2005; Malik et al., 2002) and might also be caused by circadian rhythm (Sarma et al., 1990) or by changes in autonomic nervous activity (Harada et al. -es of circadian rhythm, drug effects were compared with a time-matched vehicle control in this study. The maximum difference of QTci interval at almost the same RR interval was about 30 msec (Fig. 2C) , whereas the statis--val between vehicle control and astemizole at 10 mg/kg or dl-sotalol at 15 mg/kg was at least 30 to 40 msec (Figs.
tion in this study was beyond the QTci variation, indicatnot affect the present outcome. Another limitation is that the current study evaluated the combined results obtained from both genders (2 males and 2 females). Since women are considered more sensitive to drug-induced QT interval prolongation than men in clinic (Reinoehl et al., 1996; Benton et al., 2000) , gender difference may have affected the present results. However, there were no marked differences between males and females concerning the QTprolonging responses of astemizole and dl-sotalol in this study (individual data not shown). Therefore, the combination of data from both genders would not affect the conclusion of this study although further studies regarding gender difference are highly recommended.
In conclusion, the test drugs used in this study clearly demonstrated reactivity consistent with clinical outcome in common marmosets when the individual QT/RR correction method was applied. In addition, because of the small size of the animal, only small amounts of test drugs are required. Therefore, the present telemetry study is considered useful and cost-effective for the prediction of clinical QT-prolonging potential of drugs in the early stages of drug development.
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